Status:
COMPLETED
This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder
Lead Sponsor:
Pfizer
Conditions:
Overactive Bladder
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of the study is to assess the level of medication adherence observed among subjects receiving a specific combination of education and support materials (YourWay plan) along with ...
Detailed Description
This is a non-interventional, observational study. Study investigators will recruit symptomatic, fesoterodine-naïve subjects when they present with OAB symptoms during regularly-scheduled physician vi...
Eligibility Criteria
Inclusion
- Male or female outpatients \>=18 years old
- Eligible for receiving Toviaz 4mg or 8mg QD treatment based on the approved US label.
Exclusion
- Female subjects who are pregnant, lactating, or who are intending to become pregnant within 28 days after the completion of the study (use of contraceptives is not required to participate in the study)
- Have participated in any other studies involving study drugs within 30 days prior to entry in the study
- Subjects who have previously taken fesoterodine.
Key Trial Info
Start Date :
July 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
774 Patients enrolled
Trial Details
Trial ID
NCT00943735
Start Date
July 1 2009
End Date
November 1 2010
Last Update
December 4 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.